Trial Profile

A single-arm phase II study for Anlotinib plus Docetaxel as a second-line therapy in patients with advanced non-small-cell lung cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Docetaxel (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

09 Aug 2022 Status changed from recruiting to completed, according to Results presented at the 2022 World Conference on Lung Cancer.
09 Aug 2022 Primary endpoint (progression-free survival) has not been met, according to Results presented at the 2022 World Conference on Lung Cancer.
09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com